Adam LaBonte is a biotech leader with a passion for turning innovation into impact. As FYR’s Vice President of Commercial Development, Adam leads the company’s strategy for bringing FYR’s technologies and services to market. He oversees partnerships, customer engagement, and revenue-focused initiatives, ensuring strong alignment between commercial priorities and FYR’s scientific and operational capabilities. He’s spent over a decade helping startups and growth-stage companies in clinical oncology and NGS technologies scale and succeed. At ArcherDx, he helped launch the company’s first NGS products and played a key role in its early growth and market success. At QIAGEN, he led the clinical NGS team, guiding adoption of sequencing technologies across platforms. Most recently, at Pillar Biosciences, Adam helped expand global operations and brought OncoReveal Dx, the company’s first FDA-approved test, to market. He thrives at the intersection of science, strategy, and team building — and when he’s not doing that, he’s skiing or mountain biking in Montana with his wife and three kids.
< Back To News
April 3, 2023